The Prolistem treatment has emerged as a breakthrough for men grappling with non-obstructive azoospermia, a condition that can be incredibly challenging to address. Its efficacy and safety have been rigorously assessed and endorsed by the Turkish Urology Association, elevating it to the esteemed status of the gold standard in pre-microTESE care. This approval signifies not only its effectiveness in addressing the root causes of azoospermia but also its potential to enhance the success rates of subsequent microTESE procedures. With Prolistem paving the way as a trusted intervention, hope shines brighter for individuals navigating the complexities of male infertility.
The article: https://www.uroturk.org.tr/urolojiData/Books/991/prolistem-in-non-obstruktif-azospermide-klinik-kullanimi.pdf
We are honored to participate in the prestigious ASRM 2024 Conference in Denver, Colorado, a cornerstone event in the world of reproductive medicine. This gathering
He main point of the article “Inhibition of Spermatogonial Differentiation by Testosterone” is that testosterone can inhibit the differentiation of spermatogonia, which are the stem
Prolistem, a patented formula, has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Copyright © 2023 Prolistem®
Prolistem, a patented formula, has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Copyright © 2023 Prolistem®
